AC Immune Analyst Price Targets - Benzinga

AC Immune SA

ACIUNASDAQ

Trade with Public

Trade with Public

$2.25

-0.06-2.6%

Dern. MÀJ: Oct 27, 4:00 PM

Aperçu Actualités Prévisions de résultats ÉvénementsObjectifs de coursDonnées financières Sentiment Actionnariat Comparer Rapport sur les stocks

AC Immune Analyst Price Targets

Wall Street analyst price targets and consensus rating for AC Immune (ACIU).

Price Target Range — 12 Quarters

Analyst Consensus — 2 Analysts

2Buy

Consensus RatingBuy# Analysts2Avg. Consensus PT$10Upside to Avg. PT+344.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Voir toutes les évaluations →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
Aug 20, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
Aug 5, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
May 4, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
Mar 16, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
Nov 4, 2025	BTIG	Thomas Shrader	Maintained	Buy	$8
Sep 8, 2025	BTIG	Thomas Shrader	Maintained	Buy	$8
May 1, 2025	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$16→$12
Apr 3, 2025	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$16
Mar 14, 2025	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$16
Nov 15, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$16
Nov 6, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$16
Sep 18, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$16
May 31, 2024	BTIG	Thomas Shrader	Initiate	Buy	$8
Mar 15, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$16
Nov 13, 2023	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$16

Analyst Ratings News

PRO
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on AC Immune, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates AC Immune (NASDAQ:ACIU) with a Buy and maintains $8 price target.

Benzinga Newsdesk